HealthCare Global Enterprises Limited
HealthCare Global Enterprises Limited provides medical and healthcare services in India and internationally. The company offers cancer diagnostics services, including genomics and molecular diagnostics, digital PET, preventive oncology, physical examination, laboratory tests, home health services, digital pathology, and CTC detection; treatment services, such as medical oncology and haemato-oncology, radiation and surgical oncology, molecular imaging and theranostics, chemotherapy, robotic surgery, actinium and lutetium therapy, immunotherapy, psycho-oncology, targeted drug therapy, bone marrow transplant, pediatric oncology, organ preservation and reconstructive surgery, endocrine therapy, and liver transplant; and post care services comprising patient care, psychological support, nutrition and dietetics, multidisciplinary rehabilitation, and genetic counselling. It also provides cancer screening, interventional radiology, MRI, nephrology, clinical trial, hormone therapy, hematology, CAR T cell, translational and nuclear medicine, oncodermatology, anaesthesiology, paediatric and gynaecologic oncology, orthopaedic oncology, uro-oncology, infectious diseases, gastrointestinal and thoracic oncology, breast surgical oncology, clinical pharmacology, and pain and palliative services. In addition, the company operates multi-specialty hospitals under the HCG brand that offers inpatient and outpatient treatments with specialties in cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary, and critical care. Further, it provides oncology diagnostics services, including biomarker and translational research, and clinical research services under the Triesta Sciences brand; and fertility treatment services, including reproductive medicine, assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. HealthCare Global Enterprises Limited was founded in 1989 and is headquartered in Bengaluru, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Strong short-term liquidity β current ratio of 4.11x
Concerns1
- Low return on equity of 2.8%
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ1.28 K Cr | β | βΉ4.00 Cr | β | β | 0.3% | 9.1% | -87.9% |
| Mar 2024 | βΉ1.17 K Cr | β | βΉ33.00 Cr | β | β | 2.8% | 16.4% | -17.5% |
| Mar 2023 | βΉ1.01 K Cr | β | βΉ40.00 Cr | β | β | 3.5% | 18.4% | 5.3% |
| Mar 2022 | βΉ850.00 Cr | β | βΉ38.00 Cr | β | β | 3.5% | 39.6% | -119.8% |
| Mar 2021 | βΉ609.00 Cr | β | βΉ-192.00 | β | β | -20.8% | -11.5% | 262.3% |
| Mar 2020 | βΉ688.00 Cr | β | βΉ-53.00 | β | β | -8.6% | 7.5% | -857.1% |
| Mar 2019 | βΉ640.00 Cr | β | βΉ7.00 Cr | β | β | 1.1% | 9.2% | -72.0% |
| Mar 2018 | βΉ586.00 Cr | β | βΉ25.00 Cr | β | β | 3.9% | 7.5% | 31.6% |
| Mar 2017 | βΉ545.00 Cr | β | βΉ19.00 Cr | β | β | 3.5% | 15.7% | -480.0% |
| Mar 2016 | βΉ471.00 Cr | β | βΉ-5.00 | β | β | -1.0% | 12.1% | 150.0% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 1,310 |
| Total Expenses | 1,096 |
| EBIT / Operating Profit | 213 |
| OPM % | 16% |
| Other Income | -8 |
| Finance Costs | 89 |
| Depreciation & Amortisation | 115 |
| Profit Before Tax | 0 |
| Tax % | - |
| Net Profit / PAT | -13 |
| EPS (βΉ) | -0.94 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| HealthCare Global Enterprises Limitedthis co. | βΉ9.41 K Cr | βΉ1.28 K Cr | 513.00 | 7.95 | 49.86 | 9.1% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |